Pfizer's Lipitor (atorvastatin calcium) 80 mg reduced the risk of heart attack and stroke by 32 per cent in patients who have heart disease and chronic kidney disease compared with patients taking the 10 mg dose of Lipitor, according to a five-year Treating to New Targets (TNT) study.
"People with chronic kidney disease are more likely to die from heart disease than to develop kidney failure," said Dr. James Shepherd, a member of the TNT steering committee and clinical academic consultant, department of pathological biochemistry, University of Glasgow Medical School. "It is critical for us to find new ways to reduce cardiovascular burden in these patients. Intensive statin therapy seems to be at least part of the solution."
Whole story can be read here.
(Source: www.pharmabiz.com)
No comments:
Post a Comment